Kurt J Hilzinger
CIK 1191504 · President & COO · last filed 2026-10-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ABC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
500 W MAIN ST.
LOUISVILLE, KY 40202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HUM | Director | 19,448 | $425.42 | $8.27M | $0 | 62 | 2026-10-02 |
| OTLK | Director | 423,655 | $0.56 | $237.8K | $803.0K | 13 | 2026-05-27 |
| Outlook Therapeutics, Inc. (OTLKW) Delisted | Director | 184,947 | $0.03 | $5.5K | $97.9K | 17 | 2021-10-07 |
| Outlook Therapeutics, Inc. (ONSIW) Delisted | Director | — | — | — | $0 | 2 | 2018-11-13 |
| Outlook Therapeutics, Inc. (ONSIZ) Delisted | Director | 30,554 | — | — | $0 | 3 | 2017-10-30 |
| Cencora, Inc. (ABC) Delisted | President & COO | 176,400 | $179.98 | $31.75M | -$6.21M | 2 | 2007-02-20 |
Recent Filings · Page 4 of 10
99 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-28 | OTLK | Buy (P) | +47,160 | $69.7K | EDGAR |
| 2022-02-23 | OTLK | Buy (P) | +175,132 | $257.0K | EDGAR |
| 2022-01-04 | HUM | Grant (A) | — | $0 | EDGAR |
| 2021-10-07 | Outlook Therapeutics, Inc. (OTLKW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-04 | HUM | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | HUM | Grant (A) | — | $0 | EDGAR |
| 2021-04-02 | HUM | Grant (A) | — | $0 | EDGAR |
| 2021-03-26 | Outlook Therapeutics, Inc. (OTLKW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | HUM | Grant (A) | — | $0 | EDGAR |
| 2020-10-05 | Outlook Therapeutics, Inc. (OTLKW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.